Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (139)	3/12/2002 8:50:27 AM
From: wolfdog2	Read Replies (1) \| Respond to of 201

Tuesday March 12, 7:00 am Eastern Time Press Release SOURCE: CardioDynamics International Corporation CardioDynamics: Study on BioZ ICG Validates Noninvasive Technology as Equivalent to Pulmonary Artery Catheter Study Published in Journal of Cardiothoracic and Vascular Anesthesia SAN DIEGO, March 12, 2002 (PRIMEZONE) -- CardioDynamics (Nasdaq:CDIC - news), the innovator and global leader of Impedance Cardiography (ICG) technology, today announced that a significant ICG study was published in the February 2002 issue of peer-reviewed The Journal of Cardiothoracic and Vascular Anesthesia. The study was designed to evaluate whether measurements of cardiac index (the amount of blood pumped by the heart each minute) using BioZ noninvasive technology was equivalent to the standard invasive Pulmonary Artery Catheter. The researchers chose to study patients immediately following open-heart surgery because these patients are known to show significant hemodynamic (blood-flow) instability in the first 12 to 18 hours after surgery, and represent one of the most frequent uses of the Pulmonary Artery Catheter. The results were dramatic and revealed clinical equivalence between the BioZ and PAC measurements. Commenting on the study, lead investigator, W. Scott Sageman, M.D., stated: ``The interest in, and demand for, an accurate noninvasive method of measuring cardiac output is high. While this study demonstrated exceptional agreement between the thermodilution and BioZ-derived measurements in this patient group, its additional significance is the demonstration of an extraordinary degree of tracking of these measures over time. The potential impact, in terms of reducing morbidity while reducing costs, is substantial given the annual $1 billion burden that currently exists with PAC use in cardiac surgery procedures. This data is very encouraging regarding the role that impedance cardiography technology can play in cardiac monitoring and healthcare.'' Michael K. Perry, Chief Executive Officer of CardioDynamics, stated: ``We are pleased to see this study published in the peer-reviewed and respected Journal of Cardiothoracic and Vascular Anesthesia. This study is significant because it demonstrates that the information provided by our noninvasive BioZ is clinically equivalent to an invasive, risky and more costly procedure in patients that challenge cardiac monitoring by their blood flow instability after surgery. With each new study, the value of our proprietary ICG technology is further established, and we move closer to becoming a safe, noninvasive and cost-effective standard of care in cardiac monitoring.''